Publications by authors named "Martin Ellis"

Claim this Profile
T
The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in patients with lymphoma.
Adi Zoref-Lorenz, Jun Murakami, Ronit Gurion, Swaminathan P Iyer, Uri Abadi, Martin Ellis

Blood Adv· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of Fedratinib in Routine Treatment of Ruxolitinib-Resistant or -Refractory Patients with Primary and Post-Polycythemia Vera or Essential Thrombocythemia Myelofibrosis: A Nationwide Retrospective Study.
Adrian Duek, Alexandra Tzinman, Kira Maziuk, Assaf Levy, Martin Ellis

Acta Haematol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Weathering the HLH storm and redesigning clinical trials.
Adi Zoref-Lorenz, Martin Ellis

Blood· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baboon Syndrome after Percutaneous Coronary Intervention.
Osnat Jarchowsky Dolberg, Shani Ben Dori, Martin H Ellis, Boaz Amichai

Isr Med Assoc J· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vitamin K Antagonist Anticoagulation in Antiphospholipid Syndrome: Time in Therapeutic Range and Clinical Outcomes.
Keren Meir, Stanley Niznik, Orly Avnery, Adi Zoref-Lorenz, Nancy Agmon-Levin, Martin H Ellis

Am J Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Asciminib in Advanced-Line Treatment of Chronic Myeloid Leukemia.
Adi Shacham-Abulafia, Yulia Volcheck, Martin Ellis, Shirley Shapira, Sigal Tavor

Eur J Haematol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fedratinib for the treatment of myelofibrosis: a critical appraisal of clinical trial and "real-world" data.
Adrian Duek, Ilona Leviatan, Osnat Jarchowsky Dolberg, Martin H Ellis

Blood Cancer J· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proposals for revised International Working Group-European LeukemiaNet criteria for anemia response in myelofibrosis.
Ayalew Tefferi, Giovanni Barosi, Francesco Passamonti, Juan-Carlos Hernandez-Boluda, Prithviraj Bose, Martin Ellis

Blood· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The selenoenzyme type I iodothyronine deiodinase: a new tumor suppressor in ovarian cancer.
Adi Alfandari, Dotan Moskovich, Avivit Weisz, Aviva Katzav, Debora Kidron, Martin Ellis

Mol Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: recommendations from a global consensus group.
Steffen Koschmieder, Prithviraj Bose, Martin H Ellis, Vikas Gupta, Jean-Jacques Kiladjian

Leukemia· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
My First Patient.
Martin H Ellis

N Engl J Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and Economic Implications of Hydroxyurea Intolerance in Polycythemia Vera in Routine Clinical Practice.
Martin H Ellis, Tamar Tadmor, Naama Yekutiel, Gabriel Chodick, Moti Levy

J Clin Med· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heart valve disease in primary antiphospholipid syndrome.
Stanley Niznik, Micha J Rapoport, Orly Avnery, Mona Kidon, Ronen Shavit, Martin H Ellis

Rheumatology (Oxford)· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Queries regarding the two papers each reporting on 1000 essential thrombocythemia patients in BCJ.
Martin H Ellis

Blood Cancer J· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges in Implementing Guideline on Integrative Oncology and Pain: The Israeli Perspective.
Eran Ben-Arye, Jun Mao, Eduardo Bruera, Noah Samuels, Yael Keshet, Martin Ellis

J Pain Symptom Manage· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thrombosis in multiple myeloma: mechanisms, risk assessment and management.
Osnat Jarchowsky, Orly Avnery, Martin H Ellis

Leuk Lymphoma· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inpatient recognition and management of HLH.
Adi Zoref-Lorenz, Martin Ellis, Michael B Jordan

Hematology Am Soc Hematol Educ Program· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Direct Oral Anticoagulants in Special Patient Populations.
Asa Kessler, Yotam Kolben, Gal Puris, Martin Ellis, Mordechai Alperin

J Clin Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer" [Canc. Lett. 501 224-233].
Dotan Moskovich, Adi Alfandari, Yael Finkelshtein, Avivit Weisz, Aviva Katzav, Martin Ellis

Cancer Lett· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low molecular weight heparin for venous thromboembolism prophylaxis in general Intensive Care Unit patients: an anti-factor Xa level-based approach.
Nitzan Zohar, Martin H Ellis, Sara Dichtwald, Avraham Meyer, Edna Zohar

Minerva Anestesiol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment.
Dotan Moskovich, Yael Finkelshtein, Adi Alfandari, Amit Rosemarin, Tzuri Lifschytz, Martin Ellis

Oncogene· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Illustrated State-of-the-Art Capsules of the ISTH 2022 Congress.
Robert A Ariëns, Beverley J Hunt, Ejaife O Agbani, Josefin Ahnström, Robert Ahrends, Martin H Ellis

Res Pract Thromb Haemost· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-Dimensional Modeling of Thyroid Hormone Metabolites Binding to the Cancer-Relevant αvβ3 Integrin: Based Study.
Dror Tobi, Eilon Krashin, Paul J Davis, Vivian Cody, Martin Ellis

Front Endocrinol (Lausanne)· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of Recurrent Thrombosis in Primary Antiphospholipid Syndrome-Multicenter, Real-Life Long-Term Follow-Up.
Stanley Niznik, Micha J Rapoport, Orly Avnery, Aharon Lubetsky, Soad Haj Yahia, Martin H Ellis

Front Immunol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long Term Follow up of Patients With Primary Obstetric Antiphospholipid Syndrome.
Stanley Niznik, Micha J Rapoport, Orly Avnery, Aharon Lubetsky, Ronen Shavit, Martin H Ellis

Front Pharmacol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis